• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Retracted Note: Effects of Vitamin K2 on Osteoporosis
Curr Pharm Des. 2021;27(19):2325. doi: 10.2174/138161282719210608092930.ABSTRACTThe article entitled "Effects of Vitamin K2 on Osteoporosis, published in Curr Pharm Des 2004; 10(21): 2557-76, by Iwamoto J, Takeda T and Sato Y." has been retracted by the Editorial office of the journal Current Pharmaceutical Design, as the text, data and some figures used/referred in this review article are from sources which have been retracted or under investigation on the basis of data fabrication and falsification, authorship misconduct, duplicate publication, unethical research practices, text recycling/self-plagiarism, and unresolved ...
Source: Current Pharmaceutical Design - July 15, 2021 Category: Drugs & Pharmacology Authors: Jun Iwamoto Tsuyoshi Takeda Yoshihiro Sato Source Type: research

Research Progress on Catalpol as Treatment for Atherosclerosis
Coronary atherosclerotic heart disease, cerebrovascular disease, and peripheral artery disease are common diseases with high morbidity and mortality rates and must be addressed. Their most frequent complications, including myocardial infarction and stroke, are caused by spontaneous thrombotic occlusion and are the most frequent cause of death worldwide. Atherosclerosis (AS) is the most widespread underlying pathological change for the above diseases. Therefore, drugs that interfere with this pathophysiological process must be incorporated in the treatment. Chinese traditional and herbal drugs can effectively treat AS. With...
Source: Frontiers in Pharmacology - July 13, 2021 Category: Drugs & Pharmacology Source Type: research

Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials
CONCLUSIONS: Zoledronic acid is beneficial to reduce the incidence of fracture, while its benefits to reduce the mortality are only observed at the follow-up time of 24 months.PMID:33629326 | DOI:10.26355/eurrev_202102_24865
Source: European Review for Medical and Pharmacological Sciences - February 25, 2021 Category: Drugs & Pharmacology Authors: B He J-Q Zhao M-Z Zhang Z-X Quan Source Type: research

Regulatory role of microRNAs on PTEN signaling.
Abstract Phosphatase and tensin homolog (PTEN) gene encodes a tumor suppressor protein which is altered in several malignancies. This protein is a negative regulator of the PI3K/AKT signaling. Several transcription factors regulate the expression of PTEN in positive or negative directions. Moreover, numerous microRNAs (miRNAs) have functional interactions with PTEN and inhibit its expression. Suppression of PTEN can attenuate the response of cancer cells to chemotherapeutic agents. Based on the critical role of this tumor suppressor gene, the identification of negative regulators of its expression has practical si...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 7, 2020 Category: Drugs & Pharmacology Authors: Ghafouri-Fard S, Abak A, Shoorei H, Mohaqiq M, Majidpoor J, Sayad A, Taheri M Tags: Biomed Pharmacother Source Type: research

Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
CONCLUSIONS: Romosozumab offers an alternative for patients with a high risk of osteoporotic fractures. Clinicians should avoid romosozumab in patients with a history of myocardial infarction or stroke in the past 12 months. PMID: 32862655 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 28, 2020 Category: Drugs & Pharmacology Authors: Nealy KL, Harris KB Tags: Ann Pharmacother Source Type: research

Drug treatment strategies for osteoporosis in stroke patients.
Authors: Hsieh CY, Sung SF, Huang HK Abstract Introduction: Osteoporosis and subsequent fractures are well-recognized complications of stroke. However, drug treatment strategies for osteoporosis after stroke have been rarely discussed in the current guidelines for the management of stroke or osteoporosis.Areas covered: The authors review the epidemiology, characteristics, pathophysiology, and risk prediction of post-stroke osteoporosis and fractures. Then they provide an overview of existing evidence regarding drug treatment strategies for osteoporosis in stroke patients. They also review the effects on bone minera...
Source: Expert Opinion on Pharmacotherapy - March 11, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Geniposide Alleviates Glucocorticoid-Induced Inhibition of Osteogenic Differentiation in MC3T3-E1 Cells by ERK Pathway
Conclusion In summary, we demonstrated that geniposide alleviated GC-induced osteogenic suppression in MC3T3-E1 cells. The effects of geniposide were at least partially associated with activating ERK signaling pathway via GLP-1 receptor. Geniposide might be a potential therapeutic agent for protection against GC-induced osteoporosis. Author Contributions BX, DX, CZ, and LW participated in research design. BX, JW, YL, XW, and ZZ conducted the experiments. BX, DX, and LW contributed new reagents or analytic tools and wrote or contributed to the writing of the manuscript. BX, JW, CZ, and DX performed the data analysis. Fu...
Source: Frontiers in Pharmacology - April 17, 2019 Category: Drugs & Pharmacology Source Type: research

Plant-Derived Alkaloids: The Promising Disease-Modifying Agents for Inflammatory Bowel Disease
Conclusion This paper summarizes the current findings regarding the anti-colitis activity of plant-derived alkaloids and shows how these alkaloids exhibit significant and beneficial effects in alleviating colonic inflammation. These natural alkaloids are not only promising agents for IBD treatment but are also components for developing new wonder drugs. However, the underlying molecular mechanisms or toxicological evaluation of most plant-derived alkaloids still require much scientific research, and their actual efficacies for IBD patients have not been verified well in field research. Thus, further clinical trials to elu...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Dioscin: a diverse acting natural compound with therapeutic potential in metabolic diseases, cancer, inflammation and infections
Publication date: Available online 10 October 2018Source: Pharmacological ResearchAuthor(s): Xufeng Tao, Lianhong Yin, Lina Xu, Jinyong PengAbstractCurrently, the numbers of patients with cancer, fibrosis, diabetes, chronic kidney disease, stroke and osteoporosis are increasing fast and fast. It’s critical necessary to discovery lead compounds for new drug development. Dioscin, one active compound in some medicinal plants, has anti-inflammation, immunoregulation, hypolipidemic, anti-viral, anti-fungal and anti-allergic effects. In recent years, dioscin has reached more and more attention with its potent effects to treat ...
Source: Pharmacological Research - October 11, 2018 Category: Drugs & Pharmacology Source Type: research

Emerging strategies targeting cb2 cannabinoid receptor: biased agonism and allosterism.
Abstract During these last years, the CB2 cannabinoid receptor has emerged as a potential anti-inflammatory target in diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, ischemic stroke, autoimmune diseases, osteoporosis, and cancer. However, the development of clinically useful CB2 agonists reveals to be very challenging. Allosterism and biased-signaling mechanisms at CB2 receptor may offer new avenues for the development of improved CB2 receptor-targeted therapies. Although there has been some exploration of CB1 receptor activation by new CB1 allosteric or biased-signaling l...
Source: Biochemical Pharmacology - July 25, 2018 Category: Drugs & Pharmacology Authors: Morales P, Goya P, Jagerovic N Tags: Biochem Pharmacol Source Type: research

Pages: 1  2